American College of Radiology Announces New Appropriateness Criteria

Guidance key to help radiologists enhance quality/effectiveness of care

The American College of Radiology® (ACR®) today released the latest edition of the ACR Appropriateness Criteria®, which includes 216 diagnostic imaging and interventional radiology topics with more than 1,030 clinical variants covering 2,400 clinical scenarios.

“ACR appropriateness criteria serve a vital role in helping to ensure that patients receive the necessary, quality care that they expect from their healthcare providers,” said Mark Lockhart, MD, MPH, chair of the ACR Committee on Appropriateness Criteria. “These criteria are recognized as the national standard in radiologic care. The five new topics included in the ACR Appropriateness Criteria, including two related to pediatric care, help further ensure that patients receive the right care, for the right indication, at the right time.”

The ACR Appropriateness Criteria has been providing the most comprehensive evidence-based guidelines for diagnostic imaging selection and image guided interventional procedures since 1993.

This latest update includes five new and eight revised topics. Each topic has a narrative, an evidence table, and a literature search summary.

The new topics in today’s release are:

Recently revised topics are:

Medical providers may consult the ACR Appropriateness Criteria to fulfill Protecting Access to Medicare Act (PAMA) requirements that they consult AUC prior to ordering advanced diagnostic imaging for Medicare patients. The ACR is designated by the Centers for Medicare and Medicaid Services as a qualified Provider-Led Entity.

For more information about ACR Appropriateness Criteria, visit the ACR website. To submit feedback or comments on any topic, access the ACR Appropriateness Criteria Commenting Site .

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”